spacer
home > epc > autumn 2008 > leveraging eclinical systems
PUBLICATIONS
European Pharmaceutical Contractor

Leveraging eClinical Systems

The global biopharmaceutical industry today faces an array of daunting challenges: intense pressure to bring innovative compounds to market more quickly; rapidly rising development costs; and growing demands from regulatory and political bodies to increase drug safety and reduce prices. Faced with this difficult marketplace environment, pharmaceutical companies must find new ways to improve productivity and reduce costs throughout the clinical development process if they are to overcome these challenges in the years ahead.

The second generation of eClinical technologies – sometimes referred to a eClinical 2.0 – holds the potential to help trial sponsors improve development decision-making, reduce time to market and enhance patient safety by significantly improving data access and integration for every aspect of drug development. Yet the pharmaceutical industry’s progress in adopting these new technologies continues to lag behind that of many other businesses.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Wade Wirta, Vice President of eClinical Services at Perceptive Informatics, has extensive experience in clinical IVRS, supply chain management, and the development of global, enterprisewide IVRS software solutions supporting clinical trial execution and supply chain management. Prior to joining Perceptive, his most recent role was Director of Pfizer’s supply chain informatics group. He has extensive experience in IVRS integrated protocol administration systems; automated re-supply algorithms; adaptive randomisation; clinical reporting and tracking systems, clinical trial management systems, metrics and data warehouse development and portals.
spacer
Wade Wirta
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

MedPharm announce expansion of partnership with Palvella Therapeutics in developing a new treatment for the debilitating rare disease, pachyonychia congenita

MedPharm Ltd have announced the expansion of their partnership with Palvella Therapeutics, Inc., a Philadelphia-based biopharmaceutical company focused on developing and commercialising therapies for debilitating, rare genetic diseases. To date, MedPharm has employed its world-renowned specialist formulation expertise to support Palvella’s development of a novel, high-strength rapamycin topical formulation for application to the skin (PTX 022) as a disease-modifying treatment for pachyonychia congenita (PC). Most recently, MedPharm has made arrangements to manufacture the clinical (IMP) batches for use in Palvella’s upcoming Phase 2/3 clinical study.
More info >>

White Papers

Generating Scientific Insights by Deep Collaboration - Bridging the Big Data Divide Between Clinical and Research

BioFortis

Translational research, biomarker discovery, clinical studies and even biobanking have become increasingly data intensive.  However, generating scientific insights from such disparate “big” data sources across multiple domains is a challenge for both researchers and the informaticians that support them. Download our Deep Collaboration Whitepaper and and learn how to bridge the clinical and research divide to better explore your biomarker based trials.
More info >>

 
Industry Events

PDA Europe Annual Meeting 2019

24 June 2019, Hilton Amsterdam

Featuring updates from international regulatory agencies as well as industry, this promises to become another highlight in the 2019 event calendar and is a meeting not to be missed!
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement